Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some prescribing-information-aligned claims are correct (JAK inhibitor, indications, oral once-daily for XELJANZ XR, and general adverse reaction types as headings). However, several claims are unsupported or not assessable from the provided label excerpts, and non-label items (Canada pricing and patient assistance program) are not supported by the prescribing information provided.
Category Scores
Accurate Statements
Xeljanz XR is a Janus kinase (JAK) inhibitor.
DESCRIPTION: "tofacitinib, a JAK inhibitor"
Xeljanz XR is used to treat rheumatoid arthritis.
1.1 Rheumatoid Arthritis: "XELJANZ tablets and XELJANZ XR...indicated for the treatment of adult patients with ... rheumatoid arthritis"
Xeljanz XR is used to treat psoriatic arthritis.
1.2 Psoriatic Arthritis: "XELJANZ XR ... indicated ... adults with active PsA"
Xeljanz XR is used to treat ankylosing spondylitis.
1.3 Ankylosing Spondylitis: "XELJANZ tablets and XELJANZ XR ... indicated ... adults with active ankylosing spondylitis"
Xeljanz XR is taken orally once daily.
DESCRIPTION: "XELJANZ XR is supplied for oral administration" and 2.3 Table 1: "XELJANZ XR ... 11 mg once daily" (for patients with normal renal and hepatic function)
Unsupported Statements
Common side effects reported for Xeljanz XR can include upper respiratory tract infections.
Provided label excerpt does not list specific common side effects such as upper respiratory tract infections for XELJANZ XR; only general "clinically significant adverse reactions" headings are shown in 6.
Common side effects reported for Xeljanz XR can include headache.
No headache adverse reaction content is present in the provided label excerpts.
Common side effects reported for Xeljanz XR can include diarrhea.
No diarrhea adverse reaction content is present in the provided label excerpts.
Pfizer, the manufacturer of Xeljanz XR, may offer patient assistance programs designed to reduce out-of-pocket expenses for eligible individuals.
No patient assistance or out-of-pocket expense reduction program statements are present in the provided prescribing information excerpts.
Without insurance, a 30-day supply of Xeljanz XR in Canada can range from CAD $4,000 to $5,000 or more.
The provided prescribing information excerpts contain no pricing information and are not a source for Canada pricing.
Xeljanz XR pricing in Canada varies depending on specific dosage, pharmacy, and insurance coverage.
No pricing policy or drivers (dosage/pharmacy/insurance) are described in the provided label excerpts.
Factors influencing Xeljanz XR pricing in Canada include the manufacturer's suggested retail price.
No mention of manufacturer suggested retail price is present in the provided label excerpts.
Factors influencing Xeljanz XR pricing in Canada include pharmacy dispensing fees.
No mention of pharmacy dispensing fees is present in the provided label excerpts.
Factors influencing Xeljanz XR pricing in Canada include the extent of coverage provided by provincial drug plans or private insurance policies.
No mention of provincial drug plans or private insurance coverage is present in the provided label excerpts.
Contradictions
Important Omissions
The label's indication language includes limitations (e.g., inadequate response/intolerance to one or more TNF blockers and limitations of use; combination with biologic DMARDs or potent immunosuppressants not recommended). The AI did not mention these limitations.
Importance:
Moderate
Dose exceptions/modifications (e.g., dosing changes with renal/hepatic impairment and hemodialysis timing; dosing modifications with CYP2C19/CYP3A4 inhibitors; and laboratory-based interruptions/discontinuations) are not mentioned despite the AI stating a simple 'once daily' regimen.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The simplified dosing and adverse-effect claims are not fully supported by the provided excerpts, and omission of label limitations/dose modifications could mislead about appropriate use and safety-related management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Non-label content (patient assistance and Canada pricing) and unsupported adverse reaction examples (URI, headache, diarrhea) are included; also key label limitations and dose-modification information are omitted.
Suggested Improvement
Restrict claims to the provided label excerpts: keep indication and basic 'oral once-daily' statements for XELJANZ XR, remove Canada pricing/patient assistance statements, and avoid listing specific 'common side effects' unless supported by the label text; include key limitations of use and note that dosing is modified for renal/hepatic impairment, drug interactions, and lab abnormalities.